Johnson & Johnson (JNJ) Position Increased by Blue Edge Capital LLC
Blue Edge Capital LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 17.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,480 shares of the company’s stock after buying an additional 1,269 shares during the period. Blue Edge Capital LLC’s holdings in Johnson & Johnson were worth $1,122,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares in the last quarter. Shine Investment Advisory Services Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $177,000. Finally, Ullmann Financial Group Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at $186,000. Institutional investors and hedge funds own 65.89% of the company’s stock.
A number of equities analysts have issued reports on the company. J P Morgan Chase & Co increased their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a report on Wednesday, August 16th. Citigroup assumed coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 target price for the company. Jefferies Group set a $145.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a report on Tuesday, August 15th. BMO Capital Markets reiterated a “positive” rating and set a $152.00 target price (up previously from $145.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Finally, Royal Bank of Canada increased their target price on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $144.59.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.68 EPS. sell-side analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.38%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.
TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/johnson-johnson-jnj-position-increased-by-blue-edge-capital-llc/1759445.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.